Influence of PEG coating on the biodistribution and tumor accumulation of pH-sensitive liposomes.
Animals
Blood Circulation Time
Breast Neoplasms
/ physiopathology
Cell Line, Tumor
Drug Delivery Systems
Female
Humans
Hydrogen-Ion Concentration
Liposomes
Metabolic Clearance Rate
Mice
Mice, Inbred BALB C
Neoplasm Transplantation
Polyethylene Glycols
/ administration & dosage
Technetium
/ chemistry
Tissue Distribution
Drug delivery
Liposomes
PEGylation
Tumor targeting
Journal
Drug delivery and translational research
ISSN: 2190-3948
Titre abrégé: Drug Deliv Transl Res
Pays: United States
ID NLM: 101540061
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
pubmed:
7
9
2018
medline:
18
6
2019
entrez:
7
9
2018
Statut:
ppublish
Résumé
Liposomes are lipid vesicles widely used as nanocarriers in targeted drug delivery systems for therapeutic and/or diagnostic purposes. A strategy to prolong the blood circulation time of the liposomes includes the addition of a hydrophilic polymer polyethylene glycol (PEG) moiety onto the surface of the vesicle. Several studies claim that liposome PEGylation by a single chain length or a combination of PEG with different chain lengths may alter the liposomes' pharmacokinetic properties. Therefore, the purpose of this study was to evaluate the influence of PEG on the biodistribution of pH-sensitive liposomes in a tumor-bearing animal model. Three liposomal formulations (PEGylated or not) were prepared and validated to have a similar mean diameter, monodisperse distribution, and neutral zeta potential. The pharmacokinetic properties of each liposome were evaluated in healthy animals, while the biodistribution and scintigraphic images were evaluated in tumor-bearing mice. High tumor-to-muscle ratios were not statistically different between the PEGylated and non-PEGylated liposomes. While PEGylation is a well-established strategy for increasing the blood circulation of nanostructures, in our study, the use of polymer coating did not result in a better in vivo profile. Further studies must be carried out to confirm the feasibility of the non-PEGylated pH-sensitive liposomes for tumor treatment.
Identifiants
pubmed: 30187353
doi: 10.1007/s13346-018-0583-8
pii: 10.1007/s13346-018-0583-8
pmc: PMC6361166
mid: NIHMS1004838
doi:
Substances chimiques
Liposomes
0
Polyethylene Glycols
3WJQ0SDW1A
Technetium
7440-26-8
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
123-130Subventions
Organisme : NIGMS NIH HHS
ID : P20 GM103542
Pays : United States
Références
J Liposome Res. 2005;15(1-2):109-39
pubmed: 16194930
Cancer Res. 1995 Sep 1;55(17):3752-6
pubmed: 7641188
Int J Pharm. 2006 Apr 7;312(1-2):83-9
pubmed: 16457972
Expert Opin Drug Deliv. 2008 Jan;5(1):25-44
pubmed: 18095927
J Biol Chem. 1959 Mar;234(3):466-8
pubmed: 13641241
Biochim Biophys Acta. 1991 Sep 30;1068(2):133-41
pubmed: 1911826
Nat Rev Cancer. 2005 Mar;5(3):161-71
pubmed: 15738981
Anticancer Res. 2009 Jun;29(6):2111-20
pubmed: 19528471
Cancer Res. 1994 Feb 15;54(4):987-92
pubmed: 8313389
Nat Rev Drug Discov. 2005 Feb;4(2):145-60
pubmed: 15688077
FEBS Lett. 1990 Jul 30;268(1):235-7
pubmed: 2384160
J Mol Biol. 1965 Aug;13(1):238-52
pubmed: 5859039
Int J Pharm. 2003 Mar 6;253(1-2):121-32
pubmed: 12593943
Saudi Pharm J. 2015 Apr;23(2):182-7
pubmed: 25972739
J Pharmacol Exp Ther. 1997 Mar;280(3):1319-27
pubmed: 9067319
Eur J Pharm Biopharm. 2000 Jul;50(1):161-77
pubmed: 10840199
Int Immunopharmacol. 2003 Mar;3(3):319-28
pubmed: 12639809
J Biomed Nanotechnol. 2013 Sep;9(9):1636-43
pubmed: 23980511
Biochim Biophys Acta. 1989 May 19;981(1):27-35
pubmed: 2719971
Clin Biochem. 2005 Feb;38(2):166-74
pubmed: 15642280
Adv Drug Deliv Rev. 2001 Mar 23;47(1):55-64
pubmed: 11251245
Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11305-10
pubmed: 18685096
Mol Imaging Biol. 2016 Dec;18(6):898-904
pubmed: 27172938
Int J Pharm. 2002 May 15;238(1-2):171-80
pubmed: 11996821
Bioorg Med Chem Lett. 2010 Nov 1;20(21):6182-4
pubmed: 20850312
Crit Rev Ther Drug Carrier Syst. 1997;14(2):105-31
pubmed: 9107519
Theranostics. 2013 Dec 11;4(1):81-9
pubmed: 24396516
Bioorg Med Chem Lett. 2011 Dec 15;21(24):7373-5
pubmed: 22050889
Biochim Biophys Acta. 1992 Aug 14;1113(2):171-99
pubmed: 1510996
Chem Pharm Bull (Tokyo). 2005 Jan;53(1):27-31
pubmed: 15635224
Yakugaku Zasshi. 2005 Jan;125(1):149-57
pubmed: 15635286
Biol Pharm Bull. 2007 Jan;30(1):208-11
pubmed: 17202690
Drugs. 1998 Nov;56(5):747-56
pubmed: 9829150
J Control Release. 2001 Jul 6;74(1-3):69-75
pubmed: 11489484
J Control Release. 2015 Nov 10;217:82-91
pubmed: 26310713
J Control Release. 2005 Feb 2;102(2):427-39
pubmed: 15653162
Int J Pharm. 2011 Mar 15;406(1-2):114-6
pubmed: 21185927
Bioconjug Chem. 1995 Mar-Apr;6(2):187-94
pubmed: 7599262
Life Sci. 2007 Jan 23;80(7):659-64
pubmed: 17141809